2011 ASCO Annual Meeting Merit Award Winners - Conquer Cancer ...

First Name Last Name Degree Institution Title
Albiruni Abdul Razak MBBCh, MRCP, CCT Princess Margaret Hospital Neurocognitive function (NCF) in patients (pts) treated with chemo/bio‐radiotherapy (C/B‐
RT) for head and neck cancers (HNC).
Jasem Albarrak MD Division of Medical Oncology, British Columbia
Cancer Agency
Associations between county‐level surgeon density and colorectal cancer (CRC) mortality.
Sina Alipour MD University of British Columbia‐Department of Impact of body mass index (BMI) and body surface area (BSA) on outcomes in early stage
Medicine
colon cancer (CC).
Eitan Amir MB, ChB Division of Medical Oncology and Hematology,
Princess Margaret Hospital and University of
Toronto
Laleh Amiri‐Kordestani MD National Cancer Institute, National Institutes of
Health
Richard Baird MA, MBBS, MRCP Drug Development Unit, Royal Marsden
Hospital
25‐hydroxy vitamin‐d (VitD) and associated variables as predictors of breast cancer (BC) risk
and tamoxifen benefit in NSABP‐P1.
Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and
decay, using data from phase II and phase III clinical trials in metastatic breast cancer (MBC)
patients (Pts).
A first‐in‐human phase I study of JNJ‐26481585, a novel oral histone deacetylase inhibitor
(HDACi), in advanced cancer patients with evidence of target modulation and antitumor
activity.
Arjun Balar MD Memorial Sloan‐Kettering Cancer Center Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with
advanced/metastatic urothelial carcinoma (UC).
Justin Balko PharmD, PhD Vanderbilt University Gene expression patterns post neoadjuvant chemotherapy identify a role for the MAPK
phosphatase DUSP4 in therapeutic resistance and a stem‐like phenotype in basal‐like breast
cancer (BLBC).
Carlos Barcenas MD UT MD Anderson Cancer Center Anthracycline adherence in older patients with breast cancer.
Aditya Bardia MD, MPH Sidney Kimmel Comprehensive Cancer Center at Association of angiotensin II blockers with survival among men with prostate cancer: Results
Johns Hopkins University
from CaPSURE.
Soley Bayraktar MD University of Texas M. D. Anderson Cancer Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and
Center
nonanthracycline‐based regimens for HER2‐positive breast cancer.
Himisha Beltran MD Weill Cornell Medical College Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of
new drug targets.
Andrea Biondo MRCP Royal Marsden Hospital and The Institute of Phase Ι clinical trial of an allosteric AKT inhibitor, MK‐2206, using a once weekly (QW) dose
Cancer Research
regimen in patients with advanced solid tumors.
Stefan Boeck MD Department of Internal Medicine III, Klinikum
Grosshadern, University of Munich
Pierre Bohanes MD University of Southern California Norris
Comprehensive Cancer Center
Molecular markers of the EGFR pathway in erlotinib‐treated patients with advanced
pancreatic cancer (APC): Translational analyses of a randomized, cross‐over AIO phase III
trial.
Association of excision repair cross‐complementation group 1 (ERCC1) gene expression (GE)
with outcome in stage II‐III esophageal adenocarcinoma (EA) patients treated with
preoperative platinum‐based chemoradiation (CRT) in a phase II cooperative group study
(SWOG S0356).
Joshua Brody MD Stanford University Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results.
Timothy Burns MD, PhD The Johns Hopkins University, The Sidney Reactivation of oncogene‐induced senescence in KRAS mutant non‐small lung cancer by
Kimmel Comprehensive Cancer Center inhibition of TWIST1 .
Nicholas Campbell MD The University of Chicago Medical Center Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of the
university of chicago phase II consortium.
Vincent Castonguay MD Princess Margaret Hospital Estimation of expectedness: How reliable are the predictions for the outcome of standard
therapy in randomized phase III studies (RP3) in epithelial ovarian cancer (EOC)?
Elena Castro MD, PhD The Institute of Cancer Research and The Royal Germline BRCA2 mutations correlate with aggressive prostate cancer and adverse outcome.
Marsden NHS Foundation Trust
Fabiola Cecchi MD Urology Oncology Branch, NIH/NCI A hepatocyte growth factor antagonist engineered by site‐directed mutagenesis.
Ryaz Chagpar MD, MS University of Texas M. D. Anderson Cancer Adherence to NCCN treatment guidelines for rectal cancer: Analysis of national practice
Center
patterns.
Maggie Chon U. Cheang PhD University of North Carolina The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus non‐
anthracyclines in NCIC.CTG MA.5 randomized trial.
Daniel Christoph MD Department of Medicine, Division of Medical Predictive value of thymidylate synthase and folylpoly‐glutamate synthetase for clinical
Oncology, University of Colorado Cancer
Center, Anschutz Medical Campus
benefit from pemetrexed in malignant pleural mesothelioma.
Felipe Cruz MD FMABC Gabapentin for the prevention of chemotherapy‐induced nausea and vomiting: A pilot study.
Sinead Cuffe MD Princess Margaret Hospital, University of Adoption of adjuvant chemotherapy (ACT) for non‐small cell lung cancer (NSCLC) in the
Toronto
elderly: A population‐based outcomes study.
Tom Davidson M.D. Children's Hospital Los Angeles Outcome of head start III multi‐national protocol for newly diagnosed central nervous
system (CNS) primitive neuroectodermal tumors [pnet] of young children.
Fiona Day MBBS, BSc, FRACP Peter MacCallum Cancer Centre Cost‐effectiveness of universal hepatitis b virus screening in patients beginning
chemotherapy for solid tumors.
Jonas de Souza M.D. The University of Chicago Medical Center, Utilization and costs of non‐evidence‐based (non‐EBM) antineoplastic agents in patients with
Section of Hematology/Oncology
metastatic colon cancer (mCC).
Marzia Del Re PharmD Department of Internal Medicine ‐ University of Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants.
Pisa
Alice Dewdney MBcHB The Royal Marsden Hospital EXPERT‐c: A randomised phase II european multicentre trial of neoadjuvant capecitabine +
oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab
followed by total mesorectal excision (TME) in patients with MRI defined high risk rectal
cancer.
Vincent Dezentje MD Department of Clinical Oncology, Leiden Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a
University Medical Center
prospective cohort of early stage breast cancer patients.
Saoirse Dolly MBBS, BSc, MRCP Royal Marsden Hospital and the Institute of First‐in‐human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first‐in‐
Cancer Research
class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid
tumors.
Yvette Drew MD Northern Institute for Cancer Research, Phase II trial of the poly(ADP‐ribose) polymerase (PARP) inhibitor AG‐014699 in BRCA 1 and
Newcastle University
2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
Francois Duhoux MD Center for Human Genetics, Cliniques
universitaires Saint‐Luc, Universite catholique
de Louvain
Jennifer Eads MD University Hospitals Seidman Cancer Center,
Case Comprehensive Cancer Center, Case
Western Reserve University
PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor
prognosis but may also occur in lymphoid malignancies.
Education level but not race is associated with clinical trials barriers.

First Name Last Name Degree Institution Title
Karel Eechoute MD Erasmus University Medical Center ‐ Daniel den
Hoed Cancer Center
Correlations between imatinib trough levels and clinical benefit in gastrointestinal stromal
tumors (GIST) will be time point specific: Results of a prospective population
Hazem El‐Osta MD University of Texas M. D. Anderson Cancer
pharmacokinetic study.
Clinical characterstics and outcomes of patients with BRAF‐mutant advanced cancer in
Center
a Phase 1 clinic: The MD Anderson Cancer Center experience.
Philippe Gannon PhD Research Center of the Universite de Montreal Validation of NF‐kappab p65 as a prostate cancer prognostic marker on a large european
Hospital Center (CRCHUM) ‐ Institut du cancer
de Montreal
cohort.
Jianjun Gao MD University of Texas M. D. Anderson Cancer
Center
Mechanism of early radiographic response to imatinib in GIST.
Kathryn Gold MD The University of Texas MD Anderson Cancer Biologic risk model for recurrence in resected early stage non‐small cell lung cancer (ES
Center
NSCLC).
Jerome Graber MD, MPH Memorial Sloan‐Kettering Cancer Center Magnetic resonance (MR) perfusion imaging to differentiate early progression from
pseudoprogression following chemoradiotherapy for glioblastoma (GBM).
Fei Gu MD, PhD Tufts Medical Center Platinum‐based adjuvant chemotherapy (ACT) in elderly patients with non‐small cell lung
cancer (NSCLC) in the SEER‐medicare database: Comparison between carboplatin‐ and
cisplatin‐based regimens.
Brent Hanks M.D., Ph.D. Duke University Medical Center Role of the type III TGF‐β receptor in modulating anti‐tumor immunity during breast cancer
progression.
Sandra Harvey MBBS Peter MacCallum Cancer Centre Prospective study of breast cancer risk in mutation negative women from BRCA1 or BRCA2
mutation positive families in the Kathleen Cuningham Foundation Consortium for Research
into Familial Breast Cancer (kConFab).
Awori Hayanga MD, MPH University of Washington The association of Obesity, smoking & access to oncology Services with cancer Mortality in
the United States.
Christopher Heery MD Medical Oncology Branch, National Cancer Intraprostatic PSA‐TRICOM vaccine administration in patients with locally recurrent prostate
Institute, National Institutes of Health cancer.
Haby Henary MD Department of Investigational Cancer Final results of a first‐in‐human phase I trial of PBI‐05204, an inhibitor of AKT, FGF‐2, NF‐kb,
Therapeutics (Phase I Program), The University
of Texas MD Anderson Cancer Center
and p70S6K in advanced cancer patients.
Michael Heuser MD Department of Hematology, Hemostasis,
Oncology, and Stem Cell Transplantation,
Hannover Medical School
A polymorphism in the coding sequence of WT1 is an independent prognostic marker in
1101 lobular breast cancer patients.
Bradford Hirsch MD Duke Cancer Institute Assessment of clinical trials in oncology: An evaluation of 40,696 trials on ClinicalTrials.gov.
Marilyn Huang MD, MS University of Texas M. D. Anderson Cancer
Center
Molecular analysis of endometrial pathogenesis in lynch syndrome.
Ilaria Iacobucci PhD Department of Hematology/Oncology Seràgnoli Loss of CDKN2A gene impairs prognosis in adult BCR‐ABL1 positive acute lymphoblastic
leukemia (ALL).
Antoine Italiano MD, PhD Institut Bergonie Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal
tumors (GIST) refractory to first‐line imatinib and second‐line sunitinib.
John Jakob MD, PhD University of Texas M. D. Anderson Cancer Clinical characteristics and outcomes associated with BRAF and NRAS mutations in
Center
metastatic melanoma.
Filip Janku MD, PhD Department of Investigational Cancer Screening for PIK3CA mutations, PTEN loss and RAS /RAF mutations in early‐phase protocols
Therapeutics (Phase I Program), The University
of Texas MD Anderson Cancer Center
with PI3K/mTOR pathway inhibitors.
Irfan Jawed MD National Cancer Institute, National Institutes of
Health
High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and
dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma
harboring succinate dehydrogenase subunit b (SDHB) mutations.
Komal Jhaveri MD Memorial Sloan‐Kettering Cancer Center Risk of breast cancer (BC) after BRCA‐mutation associated ovarian cancer (BRCA‐OC):
Memorial sloan‐kettering cancer center (MSKCC) experience.
Julia Jueckstock MD Frauenklinik Innenstadt Munich University Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in breast
cancer patients – results of the german SUCCESS‐trial.
Prashant Kapoor MD Mayo Clinc Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete
response (sCR) following upfront autologous stem cell transplantation (SCT).
Polina Khrizman MD Northwestern Memorial Hospital Postoperative adjuvant chemotherapy (CTX) use in stage II/III rectal cancer patients (Pts)
treated with neoadjuvant therapy: A National Comprehensive Cancer Network (NCCN)
analysis.
Sung‐Doo Kim MD Asan Medical Center, University of Ulsan A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning
College of Medicine
regimen.
Grzegorz Korpanty MD, PhD Department of Medical Oncology, Beaumont Loss of heterozygosity (LOH) as a measure of whole genome instability in ovarian cancer
Hospital
correlates with clinical outcomes.
Joda Kuk M.D. Juravinski Cancer Centre A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine
hydrochloride for prophylaxis of radiation‐induced oral mucositis in head and neck cancer.
Annette Lim MBBS, FRACP Peter MacCallum Cancer Centre Prognostic significance of plasma osteopontin in patients with locally advanced head and
neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III
trial.
Sherene Loi MD, PhD Jules Bordet Institute Evaluation of the prognostic and predictive value of tumor‐infiltrating lymphocytes (TILs) in a
phase III randomized adjuvant breast cancer (BC) trial [BIG 2‐98] of node positive (N+) BC
comparing the addition of docetaxel to doxorubicin (A‐T) with doxorubicin (A)‐only
chemotherapy (CT).
Jason Luke MD Memorial Sloan‐Kettering Cancer Center PTC299 reduces serum VEGF levels in patients with advanced cancer: Results of a study of an
oral inhibitor of tumor VEGF synthesis.
Celine Mascaux MD, PhD Division of Medical Oncology, University of A three‐micrornas signature accurately discriminates three prognostic groups in early‐stage
Colorado Denver
NSCLC patients in the IFCT‐0002 trial.
Victor Moreno Garcia The Royal Marsden Hospital A phase I study evaluating GDC‐0941, an oral phosphoinositide‐3 kinase (PI3K) inhibitor, in
patients with advanced solid tumors or multiple myeloma.
Brian Mulherin MD Indiana Univ School of Medcn Long‐term survival with paclitaxel and gemcitabine for germ cell tumors after progression
following high‐dose chemotherapy with tandem transplants.

First Name Last Name Degree Institution Title
Saroj Niraula MBBS, MD Division of Medical Oncology and Hematology,
Princess Margaret Hospital and University of
Toronto
The balance between benefits and harms of molecular targeted agents.
Ajay Nooka MBBS Emory University Winship Cancer Center Examination of the follicular lymphoma international prognostic index (FLIPI) in the national
LymphoCare study (NLCS): A US patient cohort treated predominantly in community
practices.
Geoffrey Oxnard MD Memorial Sloan‐Kettering Cancer Center Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR‐mutant lung cancers
which recur after adjuvant TKI.
Channing Paller MD The Sidney Kimmel Comprehensive Cancer A phase II study of pomegranate extract for men with rising prostate‐specific antigen
Center
following primary therapy.
Kavitha Passaperuma MD Sunnybrook Health Sciences Centre, University Long‐term results of the Toronto magnetic resonance imaging (MRI) breast surveillance
of Toronto
study of women with BRCA1 or BRCA2 mutations.
Naveen Pemmaraju MD University of Texas M. D. Anderson Cancer Analysis of outcomes in relapsed/refractory acute promyelocytic leukemia (APL) patients
Center
(pts) treated with and without high dose chemotherapy and hematopoietic stem cell
transplantation (HCT).
Elena Pentsova MD Memorial Sloan‐Kettering Cancer Center Methotrexate (MTX) re‐challenge for recurrent primary CNS lymphoma (PCNSL).
Daniel Pollyea MD Stanford Cancer Center Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: Completed results
of the phase 1 study.
Aleix Prat MD University of North Carolina Concordance among gene‐expression‐based predictors for ER‐positive breast cancer treated
with adjuvant tamoxifen.
Brigitte Rack MD Department of Gynecology and Obstetrics, Prognostic value of CA27.29 trend during adjuvant chemotherapy and until two years
Klinikum der Ludwig‐Maximilians‐Universität thereafter in patients with primary breast cancer.
Kanwal Raghav MD The University of Texas M D Anderson Cancer Impact of low estrogen/progesterone receptor expression on survival outcomes in breast
Center
cancers previously classified as triple negative breast cancers.
Robert Ramirez DO University of Tennessee Cancer Institute Incomplete intrapulmonary lymph node retrieval with routine pathology evaluation of
resected lung cancer.
Erika Ramsdale MD University of Chicago Medical Center, Section of Relationship between components of the comprehensive geriatric assessment (CGA),
Hematology/Oncology
chemotherapy dose intensity and overall survival in a colorectal cancer (CRC) cohort age 65
and over.
James Randall MD University of California, San Diego Moores Prevalence and correlates of suicidal ideation among outpatients at a comprehensive cancer
Cancer Center
center.
Daniel Renouf MD Princess Margaret Hospital Association of the MDM2 T309G polymorphism and gastroesophageal reflux disease
(GERD) with overall survival (OS) in esophageal adenocarcinoma (EAC).
Angelica Rodrigues MD Brazilian National Cancer Institute INCA‐GYN001: Erlotinib added to cisplatin and definitive radiotherapy in untreated patients
with locally advanced squamous cell cervical carcinoma – final report of a phase II trial.
Adrian Sacher MD Department of Medical Oncology and
Hematology, Princess Margaret Hospital,
University of Toronto
Fabio Schutz MD Dana‐Farber Cancer Institute and Harvard
Medical School
Shifting patterns in the interpretation of phase III clinical trial outcomes in the treatment of
advanced NSCLC.
Genetic polymorphisms independently predict risk of recurrence in patients with localized
renal cell carcinoma: Results from a cohort study.
Alan Sears MD Brooke Army Medical Center Sequential administration of trastuzumab and a CD8 T cell‐eliciting HER‐2/neu peptide
vaccine in breast cancer patients compared to trastuzumab alone.
Xinglei Shen MD Department of Radiation Oncology, Kimmel Emerging trends in radiation therapy use among women age over 70 with stage I breast
Cancer Center, Thomas Jefferson University cancer from 2000‐2007: A population‐based analysis.
Toshio Shimizu MD South Texas Accelerated Research Therapeutics
(START) Center for Cancer Care
The clinical impact of the dual targeting strategy involving PI3K/AKT/mTOR and
RAS/MEK/ERK pathways in first‐in‐human phase I study: The START Center experience.
Michael Stauder MD Mayo Clinic Analysis of overall survival and self‐reported fatigue in patients with locally advanced
esophageal cancer: A Mayo Clinic Esophageal Adenocarcinoma and Barrett’s Esophagus
Registry Consortium study.
Iain Tan MBBS, MRCP National Cancer Centre Comparing the classification precision and prognostic performance of an intrinsic gastric
cancer signature with existing genomic signatures in 6 independent datasets.
Amir Tashakkor University of British Columbia Predicting the risk of cardiovascular comorbidity in cancer survivors.
Mateya Trinkaus MD Department of Medical Oncology, Peter Correlation of HPV status and hypoxic imaging using [18F]‐misonidazole (FMISO) PET in head
MacCallum Cancer Centre
and neck squamous cell carcinoma (HNSCC).
Jorieke van Gaal MD Radboud University Nijmegen Medical Centre Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma.
Voralak Vichapat MD, MPH. Cancer Epidemiology Unit, Division of Cancer
Studies, School of Medicine, King's College
London
Metachronous contralateral breast cancer: An analysis of risk factors and prognosis in 42,670
women in Sweden.
Andrew Weickhardt FRACP, MBBS Ludwig Institute for Cancer Research Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive
biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of
the phase III MAX study.
Daniel Weiser MD The Children's Hosp of Philadelphia Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
Sarah Yager BA University of British Columbia Gender disparities in colorectal cancer screening.
Yuki Yamane MD Division of Thoracic Oncology, National Cancer Impact of dietary habits on epidermal growth factor receptor (EGFR) mutation status of
Center Hospital East
Japanese patients with lung adenocarcinomas.
Timothy Yap
BSc, MBBS, MRCP
Royal Marsden Hospital and The Institute of
Cancer Research
Final results of a translational phase l study assessing a QOD schedule of the potent AKT
inhibitor MK‐2206 incorporating predictive, pharmacodynamic (PD), and functional imaging
biomarkers.
Tarrik Zaid MD Univ Texas MD Anderson Cancer Ctr Fibroblast growth factor receptor 4(FGFR4) expression as a prognostic indicator in high grade
serous ovarian carcinoma (HGSC): Signaling pathway, mechanism and implication for
therapeutic targeting.